Results 251 to 260 of about 280,630 (308)

18β‐Glycyrrhetinic Acid and a Nano‐Liposomal Formulation Alleviate Depression‐Like Behaviors via the Microglial mTOR‐Autophagy‐NLRP3 Axis

Advanced Science, EarlyView.
Using a novel zebrafish‐based inflammatory screening strategy, we screened and identified 18β‐glycyrrhetinic acid (18β‐GA) as a promising anti‐inflammatory candidate. We uncover a microglial mTOR–autophagy–NLRP3 axis that constitutes the mechanistic core of 18β‐GA–mediated neuroprotection.
Hua Gan, Haitao Yuan, Wenjun Zhu, Xiaokang Xie, Shen Zhou, Wenzhi Hao, Xiaowei Mo, Lian Yang, Xiaojuan Li, Junshan Liu, Lijuan Deng, Jiaxu Chen   +11 more
wiley   +1 more source

ESCRT‐Mimetic Nanodegrader Targets STING for Anti‐Inflammatory Therapy

Advanced Science, EarlyView.
A nanoplatform‐enabled targeted protein degradation strategy is presented to regulate aberrant STING signaling. STING‐ATTEC induces selective autophagic degradation of STING via formation of a STING–ATTEC–LC3 ternary complex, while the cationic FA‐LNP+ system enhances LC3 generation and targeted delivery. Together, this synergistic approach efficiently
Fuyuan Zhou, Qiming Zhai, Zhihao Yao, Qing Li, Yan Yang, Si Wang, Chao Huang, Liangjing Xin, Tao Chen, Jinlin Song   +9 more
wiley   +1 more source

A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of Monoclonal Antibodies for Prevention of COVID-19. [PDF]

Infect Dis Ther
Yalcin I, Hu L, West B, Narayan K, Holmes A, Wingertzahn MA.   +5 more
europepmc   +1 more source

Env-antibody coevolution identifies B cell priming as the principal bottleneck to HIV V2 apex broadly neutralizing antibody development. [PDF]

Sci Immunol
Habib R, Roark RS, Li H, Connell AJ, Hogarty MP, Wagh K, Wang S, Marchitto L, Skelly AN, Carey JW, Sowers KJ, Ayyanathan K, Plante SJ, Bibollet-Ruche F, Park Y, Agostino CJ, Singh A, Martella CL, Lewis E, Rando JM, Chohan N, Lora J, Ding W, Campion MS, Zhao C, Liu W, Li Y, Li X, Liang B, Chowdhury RR, Amereh K, Van Itallie E, Sheng Z, Ghosh AR, Bar KJ, Williams WB, Wiehe K, Saunders KO, Edwards RJ, Cain DW, Lewis MG, Batista FD, Burton DR, Andrabi R, Kulp DW, Haynes BF, Korber B, Shapiro L, Kwong PD, Hahn BH, Shaw GM.   +50 more
europepmc   +1 more source

SDF-1(5-67) neutralizing antibody enhances hippocampal neurogenesis and rescues cognitive deficits in chronic temporal lobe epilepsy. [PDF]

Sci Rep
Ma XY, Zhao LP, Teng QY, Tang QD, Li Q, Zhang XQ.   +5 more
europepmc   +1 more source

A die is cast: autologous neutralizing antibody resistance shapes the HIV reservoir during uninterrupted ART. [PDF]

J Clin Invest
Archin NM.
europepmc   +1 more source

Neutralizing Antibody Response Characteristics in Elderly Patients with SARS-CoV-2 Infection and Their Association with Clinical Phenotypes. [PDF]

Vaccines (Basel)
Li Y, Wang L, Ma J, Geng W, Wang Y.
europepmc   +1 more source

Assessment of SARS-CoV-2 neutralizing antibody persistence using LFIC: a prevalence study after booster doses. [PDF]

BMC Public Health
Montagud AC, Moragues R, Gabaldón-Bravo EM, Hurtado-Sánchez JA, Tuells J.   +4 more
europepmc   +1 more source

Rapid loss of activity but not serum concentration in a passive infusion clinical trial of an HIV neutralizing antibody

Mahomed S, Mkhize NN, Serebryannyy LA, Hermanus T, Kgagudi P, Kaldine H, Lambson B, Narpala SR, Basappa M, Castro M, Lin BC, Carlton K, Sands JT, Gall JG, Koup RA, Morris L, Karim QA, Moore PL, Karim SA, Doria-Rose N.   +19 more
europepmc   +1 more source